Loading...

Zoetis Inc.

ZTSNYSE
Healthcare
Drug Manufacturers - Specialty & Generic
$156.05
$-1.18(-0.75%)

Zoetis Inc. (ZTS) Stock Overview

Explore Zoetis Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

A

Score: 80.6/100

Key Financials

Market Cap69.4B
P/E Ratio27.63
EPS (TTM)$5.56
ROE0.51%

AI Price Forecasts

1 Week$173.28
1 Month$166.15
3 Months$156.10
1 Year Target$180.76

ZTS Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Zoetis Inc. (ZTS) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of A, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $180.76.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 27.63 and a market capitalization of 69.4B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Revenue Growth
8.33%
8.33%
Profit Growth
$5.63
6.06%
EPS Growth
$5.63
7.68%
Operating Margin
37.01%
10.52%
ROE
51.32%
6.06%
Dividend Yield
0.00%
15.33%

Analyst Recommendations

Strong Buy
0
Buy
2
Hold
1
Sell
0
Strong Sell
0

Price Targets

Low$160.00
Average$196.67
High$243.00

Company Profile

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.

CEO

Ms. Kristin C. Peck

Employees

13,800

Headquarters

10 Sylvan Way, Parsippany, NJ

Founded

2013

Frequently Asked Questions

;